Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The efficient total synthesis of the recently described natural substance largazole (1) and its active metabolite largazole thiol (2) is described. The synthesis required eight linear steps and proceeded in 37% overall yield. It is demonstrated that largazole is a pro-drug that is activated by removal of the octanoyl residue from the 3-hydroxy-7-mercaptohept-4-enoic acid moiety to generate the active metabolite 2, which is an extraordinarily potent Class I histone deacetylase inhibitor. Synthetic largazole and 2 have been evaluated side-by-side with FK228 and SAHA for inhibition of HDACs 1, 2, 3, and 6. Largazole and largazole thiol were further assayed for cytotoxic activity against a panel of chemoresistant melanoma cell lines, and it was found that largazole is substantially more cytotoxic than largazole thiol; this difference is attributed to differences in the cell permeability of the two substances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, romidepsin and psammaplin A (Figure 15A) contain disulfide bridges that are reduced in the intracellular environment to generate free thiols that are capable of Zn2+-chelation (Figure 15B) [84, 85].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in cellular contexts, the IC50 values of thiol HDACi decrease significantly, due to reduction/hydrolysis of prodrugs. Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Self-citation(2002) · PubMed · Cited by 732
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Research works printed but not linked: 3
- Townsend P. A., 2007, Chemical Biology, 69, 3
- Yurek-George A., 2004, J. Am. Chem. Soc., 126, 1030, 10.1021/ja039258q · DOI
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Items 101–191 of 191
Wahi, A., Jain, P., Sinhari, A., & Jadhav, H. R. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02674-4 · Cited by 25
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold
Kemp, M. M., Wang, Q., Fuller, J. H., West, N. H., Martínez, N. M., Morse, E. M., Weïwer, M., Schreiber, S. L., Bradner, J. E., & Koehler, A. N. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.098 · Cited by 24
Self-citationBhansali, P. R., Hanigan, C. L., Perera, L., Casero, R. A., & Tillekeratne, L. M. V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.009 · Cited by 22
“The cyclized core 11, upon removal of trityl group and thioesterification with octanoyl chloride, produced analogue 12 in 72% overall yield for two steps [21].”
BackgroundReddy, D. R., Ballante, F., Zhou, N., & Marshall, G. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.032 · Cited by 23
Marine natural products: synthetic aspects
Morris, J. C., & Phillips, A. J. (2010) · Natural Product Reports · doi:10.1039/b919366a · Cited by 21
Li, Y., Giulionatti, M., & Houghten, R. A. (2010) · Organic Letters · doi:10.1021/ol100596p · Cited by 21
Synthesis of the Thiazole–Thiazoline Fragment of Largazole Analogues
Diness, F., Nielsen, D. S., & Fairlie, D. P. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo201675r · Cited by 21
Macrocyclization strategies for the total synthesis of cyclic depsipeptides
Paquette, A. R., & Boddy, C. N. C. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01229h · Cited by 20
Bioactive Macrocycles from Nature
Newman, D. J., & Cragg, G. M. L. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623113-00001 · Cited by 25
Lee, H., Nihan, K., & Kwon, Y. R. (2025) · Marine Drugs · doi:10.3390/md23060233 · Cited by 21
“Largazole, a 16-membered cyclic depsipeptide from a marine Symploca strain, is a potent class I HDAC inhibitor [26,27].”
Tan, L. T. (2012) · Studies in natural products chemistry · doi:10.1016/b978-0-444-53836-9.00021-9 · Cited by 18
Su, J., Qiu, Y., Ma, K., Yao, Y., Wang, Z., Li, X., Zhang, D., Tu, Z., & Jiang, S. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.05.078 · Cited by 18
Romidepsin and the Zinc‐Binding Thiol Family of Natural Product HDAC Inhibitors
Ganesan, A. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch2 · Cited by 18
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
BackgroundJeon, H., Kim, J. H., & Kim, S. (2023) · Natural Product Reports · doi:10.1039/d3np00032j · Cited by 17
Largazole Pharmacokinetics in Rats by LC-MS/MS
Yu, M., Salvador, L. A., Sy, S. K. B., Tang, Y., Singh, R. S. P., Chen, Q.-Y., Liu, Y., Hong, J., Derendorf, H., & Luesch, H. (2014) · Marine Drugs · doi:10.3390/md12031623 · Cited by 17
“Upon completion of our first synthesis, we and, subsequently, others demonstrated that largazole is a prodrug for the potent histone deacetylase (HDAC) inhibitor [2,3], largazole thiol, which possesses selectivity for Class I HDAC isoforms, especially HDACs 1, 2 and 3, with subnanomolar potency [3–5].”
BackgroundPredicting the unpredictable: Recent structure–activity studies on peptide-based macrocycles
Wahyudi, H., & McAlpine, S. R. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.04.009 · Cited by 16
Kurisawa, N., Otomo, K., Iwasaki, A., Jeelani, G., Nozaki, T., & Suenaga, K. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00817 · Cited by 16
Thiazoles in Peptides and Peptidomimetics
Mak, J. Y. W., Xu, W., & Fairlie, D. P. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_176 · Cited by 16
Bhamboo, P., Bera, S., & Mondal, D. (2021) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100432 · Cited by 15
Therapeutic potential of marine peptides in malignant melanoma
Ahmed, S., Alam, W., Alsharif, K. F., Aschner, M., Alzahrani, F. M., Saso, L., & Khan, H. Z. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115771 · Cited by 15
Weapons in Disguise—Activating Mechanisms and Protecting Group Chemistry in Nature
Kwan, J. C., & Luesch, H. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201001562 · Cited by 14
Zhang, K., Yao, Y., Tu, Z., Liao, C., Wang, Z., Qiu, Y., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0290 · Cited by 14
Cyanobacteria as a Source for Novel Anti-Leukemic Compounds
Humisto, A., Herfindal, L., Jokela, J., Karkman, A., Bjørnstad, R., Choudhury, R. R., & Sivonen, K. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150826121124 · Cited by 14
Zhang, B., Liu, J., Gao, D., Yu, X., Wang, J., & Lei, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111672 · Cited by 14
A zinc selective oxytocin based biosensor
Mervinetsky, E., Alshanski, I., Tadi, K. K., Dianat, A., Buchwald, J., Gutiérrez, R., Cuniberti, G., Hurevich, M., & Yitzchaik, S. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01932d · Cited by 14
The role of Lawesson's reagent in the total synthesis of macrocyclic natural products
Larik, F. A., Saeed, A., Muqadar, U., El-Seedi, H. R., Faisal, M., Channar, P. A., & Mehfooz, H. (2016) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2016.1259236 · Cited by 14
Ballante, F., Reddy, D. R., Zhou, N., & Marshall, G. R. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.020 · Cited by 13
Enzymatic activation of a matrix metalloproteinase inhibitor
Jourden, J. L. M., & Cohen, S. M. (2010) · Chemical Communications · doi:10.1039/b923302d · Cited by 13
Zhang, B., Shan, G., Zheng, Y., Yu, X., Ruan, Z., Li, Y., & Lei, X. (2019) · Marine Drugs · doi:10.3390/md17060333 · Cited by 12
Junker, L. H., Li, Y., Zhu, X., Koti, S., Cerbone, R. E., Hendrick, C. L., Sangerman, J., Perrine, S. P., & Pace, B. S. (2021) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2021.102626 · Cited by 12
Synthesis of the molecular hybrid inspired by Largazole and Psammaplin A
Yu, X., Zhang, B., Shan, G., Wu, Y., Yang, F., & Lei, X. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.12.025 · Cited by 11
Frontier Between Cyclic Peptides and Macrocycles
Ermert, P., Luther, A., Zbinden, P., & Obrecht, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9504-2_9 · Cited by 11
Synthesis and biological evaluation of Santacruzamate-A based analogues
Randino, R., Gazzerro, P., Mazitschek, R., & Rodriquez, M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.026 · Cited by 11
Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole
Zhang, B., Ruan, Z., Luo, D., Zhu, Y., Ding, T., Sui, Q., & Lei, X. (2020) · Marine Drugs · doi:10.3390/md18070344 · Cited by 10
Thiazoline and Thiazole and their Derivatives
Xu, Z., & Ye, T. (2011) · Wiley eBooks · doi:10.1002/9783527634880.ch13 · Cited by 10
Cruz, D. L., Pipalia, N. H., Mao, S., Gadi, D., Liu, G., Grigalunas, M., O’Neill, M. J., Quinn, T. R., Kipper, A., Ekebergh, A., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00033 · Cited by 9
Radical‐Mediated Thiol‐Ene Strategy: Photoactivation of Thiol‐Containing Drugs in Cancer Cells
Sun, S., Oliveira, B. L., Jiménez‐Osés, G., & Bernardes, G. J. L. (2018) · Angewandte Chemie · doi:10.1002/ange.201811338 · Cited by 8
Chapter 5.5: Five-Membered Ring Systems: With N and S (Se) Atoms
Wu, Y., & Yang, B. V. (2009) · Progress in heterocyclic chemistry · doi:10.1016/s0959-6380(09)70036-4 · Cited by 9
Cyanobacterial anticancer compounds in clinical use: Lessons from the dolastatins and cryptophycins
Aesöy, R., & Herfindal, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821491-6.00003-x · Cited by 9
Xu, H., Roberts, L. R., Chou, S., Pierce, B. S., Narayanan, A., & Jones, L. H. (2017) · MedChemComm · doi:10.1039/c6md00633g · Cited by 7
Bioactive Macrocyclic Natural Products
Nor, S. M. M., Xu, Z., & Ye, T. (2011) · Wiley eBooks · doi:10.1002/9783527634880.ch16 · Cited by 6
Immunomodulatory and Therapeutic Potential of Marine Flora Products in the Treatment of Cancer
Singh, A., & Krishna, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-7607-8_7 · Cited by 7
Chotera‐Ouda, A., Wróblewska, A., Tokarz, P., & Stevens, C. V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818655-8.00129-3 · Cited by 5
Total Synthesis of Lys3 Tamandarin M: A Potential Affinity Ligand
Lassen, K. M., & Joullié, M. M. (2010) · Organic Letters · doi:10.1021/ol1024212 · Cited by 5
Promising Marine Molecules in Pharmacology
Bourguet‐Kondracki, M., & Kornprobst, J. (2014) · Wiley eBooks · doi:10.1002/9783527681501.ch11 · Cited by 5
Gupta, R. V., Begum, M. Y., Kumar, R., Gupta, J., Nagraik, R., Panda, S. P., Abomughaid, M. M., Lakhanpal, S., Avinash, D., Osmani, R. A. M., et al. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10258-7 · Cited by 5
Zang, X., Peraro, L., Davison, R. T., Blum, T. R., Vallabhaneni, D., Fennell, C. E., Cramer, S. L., Shah, H., Wholly, D. M., Fink, E. A., et al. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00854 · Cited by 4
Molecular Targets of Anticancer Agents from Filamentous Marine Cyanobacteria
Tan, L. T., & Gupta, D. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_27 · Cited by 4
“Through these synthetic efforts, it was revealed that largazole is a potent class I histone deacetylase (HDAC) inhibitor [72, 73].”
BackgroundInfluentialZhang, S., & Hu, W. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9879-7 · Cited by 4
“-binding arm, exhibited an extraordinarily potent HDAC inhibitory and antiproliferative activity (Bowers et al., 2008; Seiser et al., 2008).”
Adusumalli, S. R., Yudin, A. K., & Rai, V. (2013) · Wiley eBooks · doi:10.1002/9783527666911.ch8 · Cited by 4
Enzyme mediated concise synthesis of NH-Fmoc-S-Trityl-Cα-Methyl Cysteine
Kotapati, H. K., Lawrence, D. R., Thames, S. O., & Masterson, D. S. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.08.052 · Cited by 3
Zhao, L., Dunne, C. E., Clausen, D. J., Roberts, J. M., Paulk, J., Liu, H., Wiest, O., Bradner, J. E., & Williams, R. M. (2017) · Israel Journal of Chemistry · doi:10.1002/ijch.201600130 · Cited by 3
Self-citationMetagenome Mining Approaches for the Discovery of Marine Microbial Natural Products
Nagar, D. N., Mani, K., & Braganca, J. M. (2023) · Springer eBooks · doi:10.1007/978-981-99-6770-4_4 · Cited by 2
Charlet, J., & Liang, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800957-4.00016-3 · Cited by 2
Inagaki, Y., Wakamori, S., Katsuta, R., & Ishigami, K. (2025) · Tetrahedron Letters · doi:10.1016/j.tetlet.2025.155934 · Cited by 1
Chemistry and biology of imidazole, oxazole and thiazole alkaloids
Jin, Z. (2026) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/bs.alkal.2025.12.002 · Cited by 1
Brücksken, K. A., Lappe, L., Chen, Q.-Y., Luesch, H., Korsching, E., Reichstein, L., Marzi, A., Espinoza‐Sánchez, N. A., Habig, T., Fuentes‐Pananá, E. M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1745079 · Cited by 1
Vaske, Y. S. M., & Crews, P. (2013) · Wiley eBooks · doi:10.1002/9781118412893.ch1 · Cited by 1
“Although 23 is not commercially available at this time, its compelling biological activity as an HDAC inhibitor has captured the interest of the synthetic community and has contributed to a high incident of publication (Bowers et al. 2008, 2009). Hong & Luesch (2012) recently reviewed the literature surrounding the sy…”
BackgroundClair, J. J. L. (2009) · Royal Society of Chemistry eBooks · doi:10.1039/9781847559890-00044 · Cited by 1
Synthèses et évaluations de nouveaux composés antipaludiques et antitoxoplasmoses
Traoré, M. (2012) · theses.fr (ABES) · doi:10.70675/cd3b479az4907z4b39zb38dza8a6f5975772
Synthesis and Biological Evaluation of Histone Deacetylase Inhibitor Largazole and Analogs
Bhansali, P. R. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Histone Deacetylase Inhibitors: A Brief Overview Of Their Role And Medicinal Chemistry
Angibaud, P. R., Emelen, K. V., & Arts, J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc213
Thiophene-derivatized Fluorescent Benzamides as Possible Probes for Histone Deacetylases
Seo, Y. J. (2013) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2013.34.8.2249
Macrocycles: From Reluctant Ring Closure to Reluctant Ring Opening
Sierra, M. Á., de la Torre, M. C., & Cossío, F. P. (2013) · Wiley eBooks · doi:10.1002/9783527654628.ch6
Elucidation of the Histone Deacetylase 6 Pharmacophore
Kalin, J. H. (2012) · Figshare
Traore, M. D. M. (2016) · theses.fr (ABES) · doi:10.70675/adea84c8z9c7az4f8dz8710z31e35c676057 · Cited by 2
Iwasaki, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-1714-3_2
Suwanwong, Y., & Ploensil, P. (2025) · Oncology Reports · doi:10.3892/or.2025.9022
“Largazole thiol has been shown to be a more effective HDACi than romidepsin and spiruchostasin (106).”
Application des processus de métathèse à la synthèse de produits naturels marins
Cros, F. (2010) · theses.fr (ABES) · doi:10.70675/48cef257z8df6z47c9z9666z43939c9d721d
Hossain, S., Mujahid, M. H., Zafar, S., Ahamad, S., & Fatima, S. (2026) · Microbial Bioactives · doi:10.25163/microbbioacts.9110629 · Cited by 1
Derasp, J. S., Painsecq, F., Zhang, W., Reish, M. E., Prieto, P. L., & Hein, J. E. (2026) · Chemical Science · doi:10.1039/d6sc05647d
BindingDB (2014) · UC San Diego · doi:10.7270/q2q241pq
BindingDB (2016) · UC San Diego · doi:10.7270/q2qf8rpq
BindingDB (2013) · UC San Diego · doi:10.7270/q21j9c46
BindingDB Entry 50008128: A fluorine scan on the Zn
BindingDB (2021) · UC San Diego · doi:10.7270/q2kk9g56
BindingDB Entry 3576: Chemical phylogenetics of histone deacetylases.
BindingDB (2011) · UC San Diego · doi:10.7270/q2c53j66
BindingDB Entry 50033616: A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
BindingDB (2012) · UC San Diego · doi:10.7270/q20p10ct
BindingDB Entry 50045291: Evaluation of class I HDAC isoform selectivity of largazole analogues.
BindingDB (2016) · UC San Diego · doi:10.7270/q25q4xrz
BindingDB (2019) · UC San Diego · doi:10.7270/q2m047mp
BindingDB (2015) · UC San Diego · doi:10.7270/q2v40wrc
BindingDB (2011) · UC San Diego · doi:10.7270/q28g8kzj
Metadata
- Authors
- Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M.
- Affiliations
- Broad Institute (US)
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-07-19
- Volume
- 130
- Issue
- 33
- Pages
- 11219-11222
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC3090445
- OpenAlex
- W2082971158
- Cited by
- 165
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 3 · 2021: 10 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 12 · 2016: 9 · 2015: 12 · 2014: 13 · 2013: 10 · 2012: 10
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health (1p41gm049631-01, n01co12400-79-0-22)
- National Cancer Institute (N01CO12400, N01-CO-012400, K08CA128972, R01CA152314)
- National Institute of General Medical Sciences (GM49631)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Keywords
- largazole, total synthesis, prodrugs, class I histone deacetylase inhibitors, romidepsin, vorinostat, HDAC1, HDAC2, HDAC3, HDAC6, cytotoxicity, membrane permeability
- MeSH terms
- Vorinostat, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Enzyme Inhibitors, Humans, Hydroxamic Acids, Molecular Conformation, Stereoisomerism, Structure-Activity Relationship, Sulfhydryl Compounds, Thiazoles, Cell Line, Tumor, Depsipeptides, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.